Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)
Myocardial Infarction
About this trial
This is an interventional prevention trial for Myocardial Infarction focused on measuring AMI, Left ventricular function, Myocardial performance index, Acute myocardial infarction (AMI)
Eligibility Criteria
Inclusion Criteria: Documented AMI; MPI > 0.55 Randomized within 7 days of AMI Written informed consent Exclusion Criteria: Age < 18 years Any contraindications to angiotensin 2-receptor blockade In patients with WMSI > 1.3 treatment with ACE-inhibitor or angiotensin 2-receptor blockers In patients with WMSI <= 1.3 no initiated or planned treatment with an ACE-inhibitor. Treatment with an ACE-inhibitor must be started within 7 days Pregnancy or women of childbearing potential who are not using an effective method of contraception Other comorbid conditions that could influence the study Currently receiving an experimental study drug
Sites / Locations
- Kardiologisk Klinik, Centralsygehuset Esbjerg/Varde
Arms of the Study
Arm 1
Experimental
Irbesartan
Tablet Irbesartan 150 mg once daily